SavedAdd your journal

Journals / Fırat Tıp Dergisi / 2017 / Cilt: 22 - Sayı: 4

A Case Report of Bone Marrow Suppression Caused by Piperacillin/Tazobactam

Piperasilin/Tazobaktama Bağlı Kemik İliği Baskılanması ile Seyreden Bir Olgu Sunumu

FATMA KESMEZ CAN
Selma SEZEN
Eyüp ŞENOCAK
Pages
197–199
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case report, a clinical presentation of fever, neutropenia and thrombocytopenia in a patient on the 16 th day of PT therapy due to soft tissue infection after meniscus surgery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Piperacillin / Tazobactam (PT) is a beta lactam group of antibiotics.
📊
Key Findings & Data:Bone marrow suppression is rarely seen unwanted side effect of beta lactam antibiotics.
💡
Conclusion & Impact:In this case report, a clinical presentation of fever, neutropenia and thrombocytopenia in a patient on the 16 th day of PT therapy due to soft tissue infection after meniscus surgery.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Piperacillin / Tazobactam (PT) is a beta lactam group of antibiotics. Bone marrow suppression is rarely seen unwanted side effect of beta lactam antibiotics. In this case report, a clinical presentation of fever, neutropenia and thrombocytopenia in a patient on the 16 th day of PT therapy due to soft tissue infection after meniscus surgery.

Özet

Piperasilin/Tazobaktam (PT) beta-laktam gurubu bir antibiyotiktir. Kemik iliği baskılanması beta-laktam antibiyotiklerde nadiren görülen, istenmeyen bir yan etkidir. Bu olgu sunumunda, menisküs operasyonu sonrası yumuşak doku enfeksiyonu oluşan ve PT tedavisi verilen hastanın tedavisinin 16. gününde gelişen ateş, nötropeni ve trombositopeni tablosu sunulmuştur.

🔖

Cite This Article

CAN, F. K., SEZEN, S., ŞENOCAK, E. (2017). A Case Report of Bone Marrow Suppression Caused by Piperacillin/Tazobactam. Fırat Tıp Dergisi, Cilt: 22 - Sayı: 4, 197–199. https://ajindex.com/articles/223568

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Perry CM, Markham A. Piperacillin/tazobactam: An updated review of its use in the treatment of bacterial infections. Drugs 1999; 57: 805-43
  2. Gülay Z. Hücre duvar sentezini etkileyen antimikrobiyaller. ANKEM Derg. 2003; 17: 192-204
  3. Ekmekçi A, Yakar F, Tufan F, Demirtürk M, Çağatay A, Piperasilin/Tazobaktama bağlı kemik, iliği baskılanması ile seyreden bir olgu sunumu. Nobel Med 2007; 4: 28-30
  4. Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol 1996; 95: 611-2
  5. Yüce P, Demirdağ K, Kalkan A, Özden M, Denk A, Kılıç S S. Kan Kültürlerinde izole edilen mikroorganizmalar ve antibiyotik duyarlılıkları. ANKEM Derg 2005; 19: 17-21
  6. Peralta FG, Sánchez MB, Roíz MP, Pena MA, Tejero MA, Arjona R. Incidence of neutropenia during treatment of bonerelated infections with piperacillintazobactam. Clin Infect Dis 2003; 37: 1568-72
  7. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/ tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005; 366: 1695-703
  8. Saltoglu N, Dalkiran A, Tetiker T, et al. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect 2010; 16: 1252-7
  9. Pérez-Vázquez A, Pastor JM, Riancho JA. Immune thrombocytopenia caused by piperacillin/tazobactam. Clin Infect Dis 1998; 27: 650-1.